We’ve invested over USD $6 billion in research and development since 2008, employed hundreds of world-class scientists, and created a range of acceptable alternative products that, unlike combustible cigarettes, do not generate smoke.
The totality of the scientific evidence supports the view that smoke-free alternatives, although not risk-free and addictive, are a better choice for adult smokers compared to continued smoking. There is a lot to talk about, so let’s talk.
This pioneering group of PMI scientists and technicians work collaboratively to create reduced-risk products that mimic the sensory components of cigarettes, without smoke.
But what exactly is involved in the scientific process of driving a smoke-free product’s journey from conception to mass production?
It begins with the initial assessment of a product’s risk-reduction potential. This is based on the quality of the product’s design and on strict manufacturing quality controls to ensure it delivers a consistent aerosol.
During this early phase, tests are conducted by PMI scientists to determine if the product design will lead to an overall and significant reduction in harmful and potentially harmful constituents (HPHCs) in the aerosol, compared with cigarette smoke.
Another area of research involves measuring the level of toxicity in the aerosol of smoking alternatives compared to cigarette smoke.
PMI carries out these assessments using standard and advanced toxicology methods (comparable to those used in the pharmaceutical industry) to establish whether the reduction in HPHCs leads to a lower impact of the product aerosol on the biological mechanisms underlying smoking-related diseases.
Next up is the clinical assessment stage, in which PMI scientists study adult smokers to determine if switching to the smoke-free product reduces their exposure to harmful compounds.
The effects of using the smoke-free product are assessed against both people who have continued smoking cigarettes and those who have quit tobacco and nicotine completely.
Then, PMI scientists conduct wider perception and behavior studies to assess a smoke-free product’s potential to benefit public health.
A key area of this is understanding how different groups of people view the risk profile of a smoke-free product and how likely they are to permanently adopt it instead of smoking cigarettes, while making every effort to ensure that the product does not appeal to non-smokers, former smokers, or those trying to quit nicotine and tobacco products completely.
Finally, there’s the long-term assessment stage. This involves monitoring and researching the use of PMI’s smoke-free products once they’re available to buy, in order to assess their contribution to harm reduction. This is achieved by collating qualitative and quantitative data on the use of the smoking alternative in the real world.
At the heart of each phase of product development and testing are the PMI scientists, all of whom are determined to reshape the future of public health.
PMI’s R&D employees are working with painstaking precision and ambition to make a difference to the lives of smokers across the world.
Jean-Claude Schneider, Global Head of Product Development Programs, said: “It’s more than a big shift. It’s a revolution. It’s a complete redesign of the organization towards this new objective, which is a smoke-free future.”
It’s Time is an Initiative from Philip Morris to Advocate for Change in Public Health. It’s Time to start a conversation. It’s Time for smoking alternatives.
It’s time to unsmoke. It’s time for changes in tobacco regulation. It’s time for smoke-free alternatives. It’s time to act now.
Years of science-backed research shows our smoke-free products are better alternatives to continued smoking; but tobacco regulations often ban us from talking about them.
Learn how Philip Morris International is confronting the task to develop smoke-free alternatives and is asking society to re-imagine a world without smoke.
PMI's VP of Strategic and Scientific Communications explains why It's Time to Unsmoke.